As the biopharmaceutical industry enters a new phase of growth, manufacturers are under increasing pressure to deliver greater capacity, accelerate...
During BIO 2026, taking place June 22–25 at the San Diego Convention Center, BioPharma Boardroom spoke with Francisco Man...
As biopharmaceutical innovation continues to evolve, analytical science is playing a more strategic role in accelerating development and supporting regulat...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, arrives at a time when genomic medicine is rapidly reshaping the future of heal...
Contamination control is no longer viewed solely through the lens of compliance. Across today's biopharmaceutical manufacturing landscape, it has become a ...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, comes at a pivotal moment for emerging biotech companies. While scienti...
As biotech innovators pursue increasingly complex therapies, the path from discovery to clinical proof of concept is becoming more challenging than ever. F...
The promise of precision oncology depends not only on scientific innovation but also on successful implementation in routine clinical practice. Drawing on ...
With Proposal #6, AIDS group urges shareholders to vote to request the company produce a report on the impact of extended patent exclusivities on patie...
As regulators worldwide intensify scrutiny of per- and polyfluoroalkyl substances (PFAS), laboratories are being pushed into a new era of sensitivity, sp...
Rakuten Medical, Inc. and LOTTE Biologics announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P....
Signs Agreement to Acquire K.F. (Cambodia) Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnin...
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-...
-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...
© 2026 Biopharma Boardroom. All Rights Reserved.
